imatinib

Imatinib[1] is a good, and pretty old example: Imatinib was developed by rational drug design.

What are real chances of getting a life saving drug as good as Imatinib seeing light of the day.

It's not total bullshit - compare Imatinib on GoodRX ($787) vs CostPlus ($14) for 30 tablets.

Examples include imatinib for chronic myeloid leukemia (transforming a fatal disease into a manageable condition) and HER2-targeted drugs for breast cancer.

What's so special about Imatinib is it targets a fusion protein that is only present in a specific type of cancer.

That is, certain mutations in the protein that the drug imatinib inhibits enable cancer cells to be more resistant to the drug.

Since the development of imatinib, survival rates are basically like anybody else.

To put this in perspective, Novartis Glivec is the beta crystalline form of 'imatinib mesylate' - an already known compound which went out of patent.

The path forward looks less like penicillin and more like imatinib.

Is imatinib/gleevec used as an anti-reflux medicine as well?

> In one example of the savings the startup delivers, the leukemia treatment Imatinib typically retails at $9,657 per month.

But a more accurate title would be, Computer simulations of proteins show molecular mechanism of particular resistance mutations to imatinib that were previously characterized to increase ligand dissociation kinetics.

Imatinib (the 1st gen drug of the same class) went generic a few years ago and is 99% cheaper now.

Treatment of breast cancer and Myeloid Leukemia and with Herceptin and Imatinib.

Imatinib (Gleevac) revolutionized treatment for patients with chronic myeloid leukemia (CML).